Greenwich LifeSciences, Inc.
NASDAQ:GLSIBiotechnology
-$0.74 today
- Market cap
- $302.08M
- Beta
- 1.38
- P/E (TTM)
- -15.6
- EPS (TTM)
- -$1.49
Volume 0.71M
Average 0.14M
GLSI Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Greenwich LifeSciences, Inc.NASDAQ: GLSI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization outflow shrinks to $0
Q1 FY2026 depreciation & amortization was $0, compared with $903 a year earlier. Trailing-twelve-month depreciation & amortization was $876. Over 3 fiscal years it compounded at -21.0% a year.
Context
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $219.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.78K USD
- Year-over-year change
- -50.7%
- 4-year CAGR
- -16.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.78K | -50.7% |
| FY2024 | 2024-12-31 | 3.61K | +0.0% |
| FY2023 | 2023-12-31 | 3.61K | +0.0% |
| FY2022 | 2022-12-31 | 3.61K | +0.0% |
| FY2021 | 2021-12-31 | 3.61K | — |
Depreciation & Amortization vs competitors
How GLSI compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -75.7% is the 6th highest of 8, against a peer median of -22.2%.
- Over three fiscal years its annual growth of -21.0% compares with a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M USD | -44.0% | +24.3% | 6.0% | |
| LTM Mar 2026 | $4.89M USD | -22.2% | +22.5% | 32.5% | |
| LTM Mar 2026 | $436.09K USD | +189.3% | +454.8% | — | |
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
| LTM Mar 2026 | $251K USD | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $80.68K USD | — | -42.4% | — | |
| LTM Mar 2026 | CA$75.25K CAD | -81.1% | -37.4% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K USD | +130.4% | +136.6% | 0.4% |
| LTM Mar 2026 | $876 USD | -75.7% | -21.0% | — | |
| Peer median (excluding GLSI) | — | -22.2% | +10.7% | 5.0% | |
Competitors are the stored peer set for GLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.57M) | (7.83M) | (8.89M) | (15.79M) | (19.36M) |
| Depreciation & Amortization | 3.61K | 3.61K | 3.61K | 3.61K | 1.78K |
| Deferred Income Tax | (1.19M) | (1.75M) | 0 | 0 | 0 |
| Stock-Based Compensation | 660.58K | 1.74M | 2.38M | 7.25M | 6.8M |
| Change in Working Capital | (385.17K) | (122.27K) | 31.5K | 1.27M | 2.64M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (526.73K) | 0 | 35.47K | 921.22K | 2.07M |
| Other Working Capital | 141.57K | (122.27K) | (3.97K) | 344.11K | 568.12K |
| Other Non-Cash Items | 1.19M | 1.75M | 0 | 0 | 0 |
| Operating Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
| Capital Expenditures | 0 | (3) | 0 | 3 | 3 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 3.11M | 0 | 0 | 4.37M | 12M |
| Common Stock Repurchased | 0 | (7.54M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (275.15K) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 2.84M | (7.54M) | 0 | 4.37M | 12M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (1.46M) | (13.74M) | (6.48M) | (2.9M) | 2.09M |
| Free Cash Flow | (4.29M) | (6.2M) | (6.48M) | (7.27M) | (9.91M) |
Greenwich LifeSciences, Inc.
NASDAQ:GLSI
Intrinsic Alpha fair value
Locked
Current Price
$20.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.